Researchers at Stanford University have formulated a novel biomaterial suitable for three-dimensional (3D) bioprinting: a homogeneous composite of polycaprolactone (PCL), gelatin, and beta-tricalcium phosphate.
Stanford inventors have devised a method of multiplexing droplet reactions to analyze and identify many reactions in parallel on a single microfluidic chip using off-the-shelf flow control and valving.
Current injectable hydrogel materials have fast erosion and limited tunability of their mechanical properties at different stages of applications, limiting their biomedical applications.